首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF17 |
| Uniprot No | O60258 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-216aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMTQGEN HPSPNFNQYV RDQGAMTDQL SRRQIREYQL YSRTSGKHVQ VTGRRISATA EDGNKFAKLI VETDTFGSRV RIKGAESEKY ICMNKRGKLI GKPSGKSKDC VFTEIVLENN YTAFQNARHE GWFMAFTRQG RPRQASRSRQ NQREAHFIKR LYQGQLPFPN HAEKQKQFEF VGSAPTRRTK RTRRPQPLT |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇与FGF17重组蛋白相关的参考文献摘要概括：
1. **文献名称**: "FGF17 promotes cardiomyocyte differentiation from embryonic stem cells via the FGF receptor 2b"
**作者**: H. Huang et al.
**摘要**: 本研究利用重组人FGF17蛋白处理小鼠胚胎干细胞，证实其通过激活FGFR2b受体及下游MAPK信号通路，显著促进心肌细胞分化，为心脏再生医学提供新靶点。
2. **文献名称**: "Recombinant FGF17 enhances hippocampal neurogenesis and improves cognitive function in Alzheimer's disease models"
**作者**: S. Kim et al.
**摘要**: 通过在大鼠AD模型中注射重组FGF17蛋白，发现其可激活Wnt/β-catenin通路，增加海马区神经发生，改善认知功能障碍，提示其治疗神经退行性疾病的潜力。
3. **文献名称**: "Structural and functional characterization of human FGF17 recombinant protein produced in E. coli"
**作者**: R. Tanaka et al.
**摘要**: 该研究优化了FGF17在大肠杆菌中的可溶性表达系统，通过Ni柱层析纯化获得高活性重组蛋白，晶体结构解析显示其具有典型FGF家族β-三叶草折叠特征，体外实验验证其促血管内皮细胞增殖能力。
注：以上为模拟摘要，实际文献需通过PubMed/Google Scholar检索关键词"recombinant FGF17"或结合具体研究方向筛选。建议优先选择近五年内发表于《Nature Communications》《Cell Reports》等期刊的高相关度论文。
Fibroblast Growth Factor 17 (FGF17) is a member of the FGF family, a group of signaling proteins involved in diverse biological processes, including embryonic development, tissue repair, and metabolic regulation. As part of the FGF8 subfamily (FGF8. FGF17. FGF18), FGF17 primarily functions in a paracrine manner, binding to FGF receptors (FGFRs) with heparan sulfate proteoglycans as cofactors. It plays critical roles in neural development, particularly in midbrain patterning, cortical neurogenesis, and the maintenance of neural stem cells. Studies in animal models highlight its importance in brain development, craniofacial morphogenesis, and organogenesis.
Recombinant FGF17 is produced via genetic engineering, typically using bacterial (e.g., E. coli) or mammalian expression systems. The recombinant protein retains the functional 25-30 kDa core structure, including heparin-binding domains essential for receptor interaction. Advanced purification techniques (e.g., affinity chromatography) ensure high purity and bioactivity. Its production enables standardized research and therapeutic exploration, circumventing challenges like low endogenous expression levels and tissue-specific activity.
Research applications focus on neuroregeneration, metabolic disorders, and cancer. In neurodegenerative models, FGF17 demonstrates potential in promoting neuronal survival and synaptic plasticity. It also modulates glucose metabolism and adipose tissue function, linking it to diabetes and obesity studies. However, its role in cancer is dualistic: while it may suppress tumor growth in certain contexts, overexpression correlates with tumor angiogenesis and progression in gliomas and gastrointestinal cancers.
Despite promise, therapeutic use faces hurdles, including short half-life, stability issues, and off-target effects. Strategies like PEGylation or nanoparticle delivery aim to enhance pharmacokinetics. Ongoing studies prioritize understanding context-dependent signaling and optimizing tissue-specific targeting to unlock its clinical potential.
×
